aTyr Pharma, Inc. - Common Stock (ATYR)

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - October 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (NASDAQ: ATYR) of a class action securities lawsuit.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) investors concerning the Company’s possible violations of federal securities laws.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ATyr To Contact Him Directly To Discuss Their Options

The Law Offices of Frank R. Cruz announces an investigation of aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) on behalf of investors concerning the Company’s possible violations of federal securities laws.

A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company’s stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) --

SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) --

The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). aTyr is a clinical stage biotechnology company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of the securities laws.

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

No safety concerns identified by independent data and safety monitoring board (DSMB), which recommends continuation of study without any modifications.

Management to host conference call and webcast on March 13th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 9 – 12, 2025, in Miami, FL.

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025